OncoMatch/Clinical Trials/NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Is NCT05592626 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies STAR0602 for advanced solid tumors.
Treatment: STAR0602 — This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Allowed: KRAS wild-type
CRC (both Ras wild type and mutant)
Allowed: KRAS mutation
CRC (both Ras wild type and mutant)
Disease stage
Required: Stage III, IV, PRIMARY STAGE IV
unresectable, locally advanced, or metastatic
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loma Linda University Cancer Center · Loma Linda, California
- UC Davis Comprehensive Cancer Center · Sacramento, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- AdventHealth Celebration · Celebration, Florida
- University of Miami Sylvester Comprehensive Cancer Center · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05592626 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or IV or PRIMARY STAGE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify